Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | NRAS |
| Variant | G12R |
| Impact List | missense |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | NRAS G12R is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). G12R results in increased MAPK/ERK pathway activation in an in vitro assay (PMID: 34117033), demonstrates Erk phosphorylation similar to wild-type Nras but increased Stat5 phosphorylation in culture (PMID: 35211470), and is transforming (PMID: 34117033, PMID: 35211470), and is predicted to lead to a loss of Nras protein function and activation of downstream signaling based on the effects of HRAS G12R (PMID: 3042780, PMID: 6092966). |
| Associated Drug Resistance | |
| Category Variants Paths |
NRAS mutant NRAS act mut NRAS G12R NRAS mutant NRAS exon2 NRAS G12X NRAS G12R |
| Transcript | NM_002524.5 |
| gDNA | chr1:g.114716127C>G |
| cDNA | c.34G>C |
| Protein | p.G12R |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_002524.5 | chr1:g.114716127C>G | c.34G>C | p.G12R | RefSeq | GRCh38/hg38 |
| NM_002524 | chr1:g.114716127C>G | c.34G>C | p.G12R | RefSeq | GRCh38/hg38 |
| NM_002524.4 | chr1:g.114716127C>G | c.34G>C | p.G12R | RefSeq | GRCh38/hg38 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05638698 | Phase II | Balstilimab + QS21 + TG01 QS21 + TG01 | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (TESLA) | Active, not recruiting | USA | 0 |
| NCT05726864 | Phase Ib/II | ELI-002 | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (AMPLIFY-7P) | Active, not recruiting | USA | 0 |
| NCT04853017 | Phase Ib/II | ELI-002 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201) | Completed | USA | 0 |